SNY - Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick | Benzinga
Tuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD).
Tezspire is a registered trademark of Amgen and AstraZeneca Plc (NASDAQ:AZN).
- Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17%, although the reduction was not statistically significant, with p=0.1042.
- More reductions were observed in a prespecified subgroup of patients with baseline eosinophil count (BEC) ?150 cells/?L (37%).
- The trend in reduction was greater in a small number of subjects with BEC ?300 cells/µL.
Also Read: Amgen’s Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst ...